裂谷热病毒的反向遗传学技术：治疗方法和疫苗开发的当前及未来应用
Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.
作者信息
Bouloy Michele, Flick Ramon
机构信息
Institut Pasteur, Unité de Génétique Moléculaire des Bunyavirus, Paris Cedex, France.
出版信息
Antiviral Res. 2009 Nov;84(2):101-18. doi: 10.1016/j.antiviral.2009.08.002. Epub 2009 Aug 12.
Abstract
The advent of reverse genetics technology has revolutionized the study of RNA viruses, making it possible to manipulate their genomes and evaluate the effects of these changes on their biology and pathogenesis. The fundamental insights gleaned from reverse genetics-based studies over the last several years provide a new momentum for the development of designed therapies for the control and prevention of these viral pathogens. This review summarizes the successes and stumbling blocks in the development of reverse genetics technologies for Rift Valley fever virus and their application to the further dissection of its pathogenesis and the design of new therapeutics and safe and effective vaccines.
摘要
反向遗传学技术的出现彻底改变了RNA病毒的研究，使得操纵其基因组并评估这些变化对其生物学特性和发病机制的影响成为可能。过去几年基于反向遗传学的研究所获得的基本见解为开发用于控制和预防这些病毒病原体的设计疗法提供了新的动力。本综述总结了裂谷热病毒反向遗传学技术开发过程中的成功与障碍，以及这些技术在进一步剖析其发病机制、设计新疗法和安全有效的疫苗方面的应用。
相似文献
1
Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.裂谷热病毒的反向遗传学技术：治疗方法和疫苗开发的当前及未来应用
Antiviral Res. 2009 Nov;84(2):101-18. doi: 10.1016/j.antiviral.2009.08.002. Epub 2009 Aug 12.
2
Reverse genetics of negative-stranded RNA viruses: a global perspective.负链RNA病毒的反向遗传学：全球视角
FEMS Microbiol Lett. 2005 Mar 1;244(1):9-18. doi: 10.1016/j.femsle.2005.01.046.
3
Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs.用裂谷热病毒cDNA构建体免疫小鼠后免疫反应及保护效力的表征
Virol J. 2009 Jan 17;6:6. doi: 10.1186/1743-422X-6-6.
4
Modifying the NSs gene to improve live-attenuated vaccine for Rift Valley fever.改造NSs基因以改进裂谷热减毒活疫苗。
Expert Rev Vaccines. 2012 Nov;11(11):1283-5. doi: 10.1586/erv.12.106.
5
Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.单周期可复制的裂谷热病毒突变体作为安全的候选疫苗
Virus Res. 2016 May 2;216:55-65. doi: 10.1016/j.virusres.2015.05.012. Epub 2015 May 27.
6
Rift valley fever: recent insights into pathogenesis and prevention.裂谷热：发病机制和预防的最新见解。
J Virol. 2011 Jul;85(13):6098-105. doi: 10.1128/JVI.02641-10. Epub 2011 Mar 30.
7
Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates.减毒活裂谷热病毒候选疫苗在非人灵长类动物中的效力和减毒效果。
PLoS Negl Trop Dis. 2018 May 9;12(5):e0006474. doi: 10.1371/journal.pntd.0006474. eCollection 2018 May.
8
Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome.给予来自口蹄疫病毒基因组的干扰素诱导RNA转录本后对小鼠裂谷热病毒感染的保护作用。
Antiviral Res. 2014 Sep;109:64-7. doi: 10.1016/j.antiviral.2014.06.010. Epub 2014 Jun 25.
9
[Study on DNA immune of envelope protein gene of Rift Valley Fever Virus].[裂谷热病毒包膜蛋白基因的DNA免疫研究]
Wei Sheng Wu Xue Bao. 2007 Aug;47(4):677-81.
10
The Change P82L in the Rift Valley Fever Virus NSs Protein Confers Attenuation in Mice.裂谷热病毒 NSs 蛋白中的 Rift Valley Fever Virus NSs 蛋白中的 P82L 突变导致在小鼠中减毒。
Viruses. 2021 Mar 24;13(4):542. doi: 10.3390/v13040542.
引用本文的文献
1
Mysterious Oropouche virus: Transmission, symptoms, and control.神秘的奥罗普切病毒：传播、症状与防控
Infect Med (Beijing). 2025 Mar 17;4(2):100177. doi: 10.1016/j.imj.2025.100177. eCollection 2025 Jun.
2
Bunyaviruses: Expression of Recombinant Glycoproteins from Insect Cells.布尼亚病毒：昆虫细胞中重组糖蛋白的表达
Methods Mol Biol. 2025;2893:181-191. doi: 10.1007/978-1-0716-4338-9_14.
3
Novel replication-competent reporter-expressing Rift Valley fever viruses for molecular studies.用于分子研究的新型具有复制能力的表达报告基因的裂谷热病毒。
J Virol. 2025 Jan 31;99(1):e0178224. doi: 10.1128/jvi.01782-24. Epub 2024 Dec 12.
4
Segmented, Negative-Sense RNA Viruses of Humans: Genetic Systems and Experimental Uses of Reporter Strains.人类分段负义 RNA 病毒：报告株的遗传系统和实验用途。
Annu Rev Virol. 2023 Sep 29;10(1):261-282. doi: 10.1146/annurev-virology-111821-120445.
5
Identification of an Arylnaphthalene Lignan Derivative as an Inhibitor against Dengue Virus Serotypes 1 to 4 (DENV-1 to -4) Using a Newly Developed DENV-3 Infectious Clone and Replicon.利用新开发的登革病毒 3 型感染性克隆和复制子鉴定出一种芳基萘木脂素衍生物作为抗登革病毒血清型 1 至 4（DENV-1 至 -4）的抑制剂。
Microbiol Spectr. 2023 Aug 17;11(4):e0042323. doi: 10.1128/spectrum.00423-23. Epub 2023 Jun 28.
6
Development and Characterization of a Reverse Genetics System for a Human-Derived Severe Fever With Thrombocytopenia Syndrome Virus Isolate From South Korea.韩国人源严重发热伴血小板减少综合征病毒分离株反向遗传学系统的建立与特性分析
Front Microbiol. 2021 Nov 11;12:772802. doi: 10.3389/fmicb.2021.772802. eCollection 2021.
7
Innate Immunity to Orthohantaviruses: Could Divergent Immune Interactions Explain Host-specific Disease Outcomes?先天免疫对抗 Orthohantaviruses：不同的免疫相互作用能否解释宿主特异性疾病结局？
J Mol Biol. 2022 Mar 30;434(6):167230. doi: 10.1016/j.jmb.2021.167230. Epub 2021 Sep 4.
8
Development of Rice Stripe Tenuivirus Minireplicon Reverse Genetics Systems Suitable for Analyses of Viral Replication and Intercellular Movement.适用于分析病毒复制和细胞间运动的水稻条纹叶枯病毒微型复制子反向遗传系统的开发
Front Microbiol. 2021 Mar 23;12:655256. doi: 10.3389/fmicb.2021.655256. eCollection 2021.
9
Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge.编码蓝舌病病毒（BTV）抗原的裂谷热重组病毒：在 BTV-4 挑战下的免疫和疗效研究。
PLoS Negl Trop Dis. 2020 Dec 4;14(12):e0008942. doi: 10.1371/journal.pntd.0008942. eCollection 2020 Dec.
10
Rift Valley Fever: Important Considerations for Risk Mitigation and Future Outbreaks.裂谷热：降低风险及应对未来疫情爆发的重要考量因素
Trop Med Infect Dis. 2020 Jun 2;5(2):89. doi: 10.3390/tropicalmed5020089.
本文引用的文献
1
The αGal HyperAcute(®) Technology: enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade.αGal 超敏（®）技术：利用天然的αGal 介导的人畜共患病阻断作用增强抗病毒疫苗的免疫原性。
Zoonoses Public Health. 2009 Aug;56(6-7):391-406. doi: 10.1111/j.1863-2378.2008.01191.x.
2
Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody.与天然抗Gal抗体在体内形成免疫复合物的疫苗免疫原性增强的机制。
Vaccine. 2009 May 18;27(23):3072-82. doi: 10.1016/j.vaccine.2009.03.019. Epub 2009 Mar 28.
3
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.T-705（法匹拉韦）及相关化合物：新型RNA病毒感染的广谱抑制剂。
Antiviral Res. 2009 Jun;82(3):95-102. doi: 10.1016/j.antiviral.2009.02.198. Epub 2009 Mar 6.
4
NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase.裂谷热病毒的NSs蛋白诱导双链RNA依赖性蛋白激酶的特异性降解。
J Virol. 2009 May;83(9):4365-75. doi: 10.1128/JVI.02148-08. Epub 2009 Feb 11.
5
Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation.裂谷热病毒NSs蛋白促进蛋白激酶PKR的转录后下调并抑制eIF2α磷酸化。
PLoS Pathog. 2009 Feb;5(2):e1000287. doi: 10.1371/journal.ppat.1000287. Epub 2009 Feb 6.
6
Potential for North American mosquitoes to transmit Rift Valley fever virus.北美蚊子传播裂谷热病毒的可能性。
J Am Mosq Control Assoc. 2008 Dec;24(4):502-7. doi: 10.2987/08-5791.1.
7
An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus.一种源自甲病毒复制子的裂谷热病毒候选疫苗。
Epidemiol Infect. 2009 Sep;137(9):1309-18. doi: 10.1017/S0950268808001696. Epub 2009 Jan 27.
8
Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus.用病毒样颗粒进行疫苗接种可保护小鼠免受裂谷热病毒的致死性感染。
Virology. 2009 Mar 15;385(2):409-15. doi: 10.1016/j.virol.2008.12.012. Epub 2009 Jan 20.
9
Efficient production of Rift Valley fever virus-like particles: The antiviral protein MxA can inhibit primary transcription of bunyaviruses.裂谷热病毒样颗粒的高效生产：抗病毒蛋白MxA可抑制布尼亚病毒的初级转录。
Virology. 2009 Mar 15;385(2):400-8. doi: 10.1016/j.virol.2008.12.011. Epub 2009 Jan 19.
10
Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs.用裂谷热病毒cDNA构建体免疫小鼠后免疫反应及保护效力的表征
Virol J. 2009 Jan 17;6:6. doi: 10.1186/1743-422X-6-6.
Zotero 插件